The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as BRAF / MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’ Tafinlar + Mekinist, and, more recently, Pfizer / Array BioPharma’s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underpenetrated BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.
- How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug treatment rates increase over the forecast period?
- What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?
- Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
- What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?
Geographies: United States, EU5, Japan.
Primary Research: 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.
Emerging therapies: Phase III: 9 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Liseth Parra; Oliver Blandy
Liseth M Parra, Ph.D., is an analyst on the Oncology team at Decision Resources Group with an extensive background in oncology research and market analysis. Prior to joining DRG, Liseth generated valuable offerings and comprehensive strategic solutions for leading R&D clinical, commercial, and marketing teams in oncology as a research analyst for Kantar Health and as an independent consultant. Liseth holds a Ph.D. in neurobiology from the University of California, San Diego and completed a postdoctoral fellowship in oncology at the Brigham and Women’s Hospital, Harvard Medical School. Liseth supports DRG’s syndicated oncology research offerings, focusing on malignant melanoma disease landscape and forecast analysis.
Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.
Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.
Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.